Does syphilis affect HIV in the brain?
|
|
- Sharon Gilbert
- 5 years ago
- Views:
Transcription
1 CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Does syphilis affect HIV in the brain? 1 February 2011 Outbreaks of sexually transmitted infections (STIs) are occurring in Canada and other high-income countries. STIs can cause inflammation, sores, ulcers or lesions on or inside delicate ano-genital tissues. In addition to the specific damage that each STI causes, the inflammation and sores caused by STIs can provide a portal for HIV and other germs to be transmitted. Researchers have noted several similarities between syphilis and HIV, including the following: Co-infection with syphilis and HIV is relatively common because both microbes are sexually transmitted. The germs that cause syphilis (called treponemes or spirochetes) can invade and replicate inside the brain and spinal cord (the central nervous system, or CNS) shortly after they invade the body. HIV also enters the CNS shortly after infection and replicates inside cells of the immune system that are in the CNS. Syphilis is particularly problematic because it can damage such organs as the heart, kidney, liver, eyes and brain. There are reports of increased rates of syphilis among some men who have sex with men, some of whom are also HIV-positive. Researchers at the University of California at San Diego, a centre for excellence in neuroaids research, are concerned about the impact of both HIV and syphilis on the brain. This concern arises in part because HIV infection is generally associated with an increased risk for neurocognitive impairment. A large study has found that such impairment can persist despite the use of potent anti-hiv therapy, commonly called ART or HAART. If treponemes invade the CNS, there is the possibility that they might increase inflammation. This, in turn, can increase the production of HIV and its proteins, which are toxic for brain cells. Ultimately, if such effects persist, there is the possibility that they could slowly degrade the brain, amplifying the possibility of neurocognitive decline. The San Diego team has found that HIV-positive people with neurosyphilis had higher levels of HIV replication in the brain than other HIV-positive people without neurosyphilis. The possible reasons for these findings and their implications are explored in this report. Study details Researchers collected extensive health data from 225 HIV-positive participants who were being monitored as part of a larger long-term study. All participants received extensive neurological, psychiatric and medical assessments. With regard to syphilis, participants blood samples were first screened for antibodies suggestive of having syphilis, and positive results were confirmed with other tests. Similar testing was done on cerebrospinal fluid (CSF), in which the brain and spinal cord float. The basic profile of participants was as follows: age 40 years 1% females, 99% males current CD4+ count 357 cells nadir (lowest-ever) CD4+ count 191 cells
2 viral load in the blood 1,600 copies/ml 60% of participants were taking HAART In summary, study volunteers were mostly men around the age of 40 with a history of immune deficiency. Results Based on the reports from laboratory testing, researchers divided participants into three groups as follows: 23 people with neurosyphilis 42 people with systemic syphilis who did not have neurosyphilis 160 people who tested negative for syphilis Participants who tested positive for syphilis were asked for permission to contact their family doctor so that treatment for syphilis could be coordinated. Syphilis before neurosyphilis Most participants who had neurosyphilis reported that they had been diagnosed with and treated for syphilis in the past. According to the research team, this previous treatment for syphilis had been appropriate ; however, details about specific treatment were not published. Viral load in the blood and CSF CSF viral load was greatest in people classified as having neurosyphilis, followed by people classified as having systemic syphilis, followed by people classified as not having syphilis. Researchers did analyses of the anti-hiv regimens that all three groups of participants took but found that there were no significant differences between the regimens and their ability to penetrate the brain. Further analysis that took many factors into account a multivariate analysis found that the effects of neurosyphilis and syphilis on viral load in the CSF were not affected by viral load in the blood. Putting together the puzzle Based on the data gathered, the research team suggests that syphilis co-infection may increase viral load in the CSF. However, researchers were intrigued by their findings because none of the participants classified as having neurosyphilis appeared to have signs/symptoms suggestive of active neurosyphilis and their prior treatment for syphilis was considered appropriate. Moreover, routine laboratory tests used to assess the severity of neurosyphilis did not suggest rampant infection in the CNS. The researchers note that both treponemes and HIV affect sentinel cells of the immune system called macrophages. These cells alert the immune system to the presence of invading germs. Macrophages can do so because that is one of their major roles. Activated macrophages release chemical messengers called cytokines that help activate and inflame the local immune system in the CNS so that it can better identify and control invading germs. The San Diego team suggests that the immune system in the CNS of some HIV-positive people who have had syphilis or neurosyphilis appears to become permanently activated. This activation has an inadvertent effect of making immune system cells susceptible to HIV infection. As these cells become infected with HIV, they are transformed into miniature virus factories, spewing out more copies of HIV, raising viral load and releasing proteins that are toxic to brain cells. The researchers also note that ongoing immune activation (triggered by syphilis) in the brains of HIV-positive people could predispose them to a higher frequency of neurocognitive impairment. Although neurocognitive impairment was not assessed in the present study, a previous study also conducted at the University of California at San Diego in the mid-1990s assessed and compared neurocognitive impairment in 453 HIV-positive and 219 HIV-negative volunteers who had a history of syphilis or gonorrhea. Researchers found that participants who were HIV positive and who had a history of syphilis or gonorrhea tended to have neurocognitive deficits compared to HIV-negative
3 people with syphilis or gonorrhea. This difference occurred regardless of education level and anti-hiv drugs and was present even though participants had modest CD4+ cell counts (460 cells). Other studies in the present era have found that systemic syphilis can reduce the CD4+ counts of HIV-positive people. However, once syphilis is treated, CD4+ counts return to their pre-syphilis levels. Taken together, the two neurology studies done at the University of California at San Diego raise the possibility that even after syphilis has been treated appropriately it may adversely affect the immune system in subtle ways such as causing immune activation in the CNS. Immune activation is not a trivial problem; it appears to play a role in many of the complications that are appearing in HIV-positive people, even those whose infections are under control with ART. The present study was retrospective in design. Such studies can inadvertently cause biased interpretation of data. The San Diego team took pains to reduce the possibility of inadvertent bias, however, this problem cannot entirely be ruled out. Based on the results of the present study, the San Diego team suggests that future studies are necessary to assess whether co-infection with HIV and syphilis is indeed linked to greater rates of neurocognitive impairment. Hopefully such studies will include high-tech tests such as PCR and other assessments for treponemes in the brain. Acknowledgement We thank Ronald Ellis, MD, PhD, University of California at San Diego, for expert review. REFERENCES: Sean R. Hosein 1. Fang L, Oliver A, Jayaraman G, Wong T, et al. Trends in age disparities between younger and middle-age adults among reported rates of Chlamydia, gonorrhea, and infectious syphilis infections in Canada: Findings from 1997 to Sexually Transmitted Infections Jan;37(1): van de Laar MJ. HIV/AIDS and other STIs in men who have sex with men a continuous challenge for public health. Eurosurveillance Nov 26;14(47). pii: Savage EJ, Hughes G, Ison C, et al. Syphilis and gonorrhoea in men who have sex with men: a European overview. Eurosurveillance Nov 26;14(47). pii: Sullivan PS, Hamouda O, Delpech V, et al. Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe and Australia, Annals of Epidemiology Jun;19(6): Zablotska IB, Imrie J, Prestage G, et al. Gay men s current practice of HIV seroconcordant unprotected anal intercourse: serosorting or seroguessing? AIDS Care Apr;21(4): Lukehart SA, Hook EW 3rd, Baker-Zander SA, et al. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Annals of Internal Medicine 1988 Dec 1;109(11): Tramont EC. Treponema pallidum (syphilis). In: Mandell GL, Bennett JE and Dolin R, editors. Principles and Practice of Infectious Diseases. Sixth ed. Philadelphia: Elsevier; P Lukehart SA. Syphilis. In: Fauci AS, Braunwald E, Kasper DL, editors. Harrison s Principles of Internal Medicine. 17th ed. McGraw-Hill Companies, Inc.; P Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of Neurovirology Dec 21. [Epub ahead of print]. 10. Heaton RK, Clifford DB, Franklin DR Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology Dec 7;75(23): de Almeida SM, Bhatt A, Riggs PK, et al. Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis. Journal of Neurovirology Feb;16(1): Wallace MR, Heaton RK, McCutchan JA, et al. Neurocognitive impairment in human immunodeficiency virus infection is correlated with sexually transmitted disease history. Sexually Transmitted Diseases Aug;24(7): Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. Journal of Infectious Diseases Feb 1;189(3): Marra CM, Tantalo LC, Sahi SK, et al. CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected
4 patients with syphilis. Sexually Transmitted Diseases May;37(5): Champion CI, Blanco DR, Lovett MA. Quantitative assessment of protection in experimental syphilis. Infection and Immunity Sep;73(9): Deeks SG. HIV infection, inflammation, immunosenecence and aging. Annual Review of Medicine Feb 18;62:
5 Produced By: 555 Richmond Street West, Suite 505, Box 1104 Toronto, Ontario M5V 3B1 Canada Phone: Toll-free: Fax: Charitable registration number: RR Disclaimer Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question. CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature. CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders. Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs. Permission to Reproduce This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at CATIE Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada. Available online at:
Viral infections Hep C and HIV linked to hip fractures
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Viral infections Hep C and HIV linked to hip fractures 22 November 2012 Infection with hepatitis C virus (HCV) and HIV causes inflammation,
More informationLong-acting drugs for HIV
From TreatmentUpdate 222 Long-acting drugs for HIV Long-acting formulations of two anti-hiv drugs are being tested in clinical trials: cabotegravir an experimental integrase inhibitor made available in
More informationFrom Safer Sex Guide. Using condoms
From Safer Sex Guide Using condoms Click to enlarge Using condoms correctly and consistently can signifiantly reduce your chances of passing or getting HIV and other STIs. There are two types of condoms
More informationUnderstanding risk by sex act
From Safer Sex Guide Understanding risk by sex act Kissing (with tongue) Chlamydia Avoid kissing if you or your partners have sores on the lips or mouth, or if one of you has an active oral infection (such
More informationExploring the risks of liver cancer after successful treatment for hepatitis C virus
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring the risks of liver cancer after successful treatment for hepatitis C virus 11 June 2013 In Canada and other high-income countries,
More informationThe debut of velpatasvir for hepatitis C
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. The debut of velpatasvir for hepatitis C 23 November 2015 Hepatitis C virus (HCV) can be grouped into six major strains, or genotypes,
More informationDoravirine vs. darunavir
From TreatmentUpdate 220 Doravirine vs. darunavir Doravirine is an experimental non-nuke that is undergoing phase III clinical trials. It is designed to be effective against most strains of HIV that are
More informationDetailed results from the START study
From TreatmentUpdate 210 Detailed results from the START study Researchers in 35 countries across all continents collaborated to recruit 4,685 HIV-positive adults who were in good health for START. Upon
More informationStudy finds PEP not 100% effective in preventing HIV infection
From TreatmentUpdate 152 Study finds PEP not 100% effective in preventing HIV infection Some doctors and nurses who care for PHAs may sustain needle-stick injuries. This raises the possibility that they
More informationNorthern Alberta preventing HIV transmission to babies
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Northern Alberta preventing HIV transmission to babies 25 June 2009 Since 1996 the widespread availability of combination therapy for HIV
More informationHere are some of the steps (greatly simplified) and gaps that can occur in the HIV Treatment Cascade:
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Alberta Reducing deaths by strengthening the HIV Treatment Cascade 20 May 2014 In Canada and other high-income countries, deaths from AIDS-related
More informationPatient navigators for hepatitis C patients found useful in New York City
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Patient navigators for hepatitis C patients found useful in New York City 4 January 2017 Hepatitis C virus (HCV) infects and injures the
More informationA study about switching from TDF to TAF
From TreatmentUpdate 211 A study about switching from TDF to TAF Researchers enrolled HIV-positive participants who were taking regimens containing TDF (tenofovir disoproxil fumarate), the original formulation
More informationNorwegian HIV vaccine Very modest results seen in recent clinical trial
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Norwegian HIV vaccine Very modest results seen in recent clinical trial 21 February 2012 Although HIV infection can be treated with combination
More informationHepatitis C treatment program improves access to housing, income and healthcare
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Hepatitis C treatment program improves access to housing, income and healthcare 13 July 2015 Despite high rates of hepatitis C virus (HCV)
More informationHow are testing technologies used to diagnose HIV infection?
HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including where the test is conducted,
More informationIt is a good idea for anyone having sex to get tested regularly and treated for STIs if necessary.
FACTSHEET Sexually Transmitted Infections and HIV Transmission This is one of a series of fact sheets about the biology of HIV transmission. The fact sheets review specific biological factors that make
More informationPost-exposure prophylaxis (PEP)
Post-exposure prophylaxis (PEP) Summary Post-exposure prophylaxis, or PEP, is a way to help prevent the transmission of HIV in an HIV-negative person who may have been recently exposed to HIV. It involves
More informationThe epidemiology of HIV in Canada
FACTSHEET The epidemiology of HIV in Canada This fact sheet provides a snapshot of the HIV epidemic in Canada. It is one of a series of fact sheets on the epidemiology of HIV and hepatitis C in Canada.
More informationExploring risks for MRSA infection A tale of two studies
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring risks for MRSA infection A tale of two studies 2 March 2012 A group of bacteria called S. aureus (Staphylococcus aureus ) are
More informationStudy finds sustained-release dexamfetamine is promising for reducing cocaine use
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Study finds sustained-release dexamfetamine is promising for reducing cocaine use 27 April 2016 Depending on the circumstances, the use
More informationIs there a link between niacin and stroke?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Is there a link between niacin and stroke? 7 July 2011 A large American-Canadian study called Aim-High was halted 18 months ahead of schedule.
More informationIncreased risk for dialysis found with HIV infection
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Increased risk for dialysis found with HIV infection 12 September 2013 In high-income countries such as Canada, Australia and the U.S.
More informationStudy explores risk for shingles in the current era
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Study explores risk for shingles in the current era 19 February 2015 Infection with VZV (varicella zoster virus), a member of the herpes
More informationLimiting the spread of hepatitis C virus with Treatment as Prevention (TasP)
From TreatmentUpdate 197 Limiting the spread of hepatitis C virus with Treatment as Prevention (TasP) The idea of Treatment as Prevention, or TasP, has been proposed and is being implemented in some regions
More informationThe epidemiology of hepatitis C in Canada
The epidemiology of hepatitis C in Canada FACT SHEET Published 2017 This fact sheet provides a snapshot of the hepatitis C epidemic in Canada. It is one of a series of fact sheets providing epidemiological
More informationAmerican Academy of Pediatrics issues statement on infant feeding and HIV transmission
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. American Academy of Pediatrics issues statement on infant feeding and HIV transmission 7 February 2013 The widespread availability of potent
More informationKey messages on hepatitis A for clients are available at the end of this fact sheet.
Hepatitis A Summary Hepatitis A is an infection caused by a virus that can be sexually transmitted. Infection with hepatitis A results in inflammation of the liver (hepatitis). Hepatitis A is transmitted
More informationSuperbug increasing among HIV positive people
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Superbug increasing among HIV positive people 24 September 2007 Bacteria are a common source of problems, causing a variety of infections,
More informationHepatitis A FACTSHEET. Summary. What is hepatitis A?
FACTSHEET Hepatitis A Summary Hepatitis A is an infection caused by a virus that can be sexually transmitted. Infection with hepatitis A results in inflammation of the liver (hepatitis). Hepatitis A is
More informationHIV and the immune system linked to heart disease in women
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. HIV and the immune system linked to heart disease in women 26 September 2013 The widespread availability of potent combination anti-hiv
More informationPre-exposure prophylaxis (PrEP)
FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.
More informationHIV testing technologies
HIV testing technologies HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including
More informationSchizophrenia and HIV Study underscores serious issues associated with dual diagnoses
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Schizophrenia and HIV Study underscores serious issues associated with dual diagnoses 15 July 2015 Several studies have found that some
More informationTHE POWER OF UNDETECTABLE. What you need to know about HIV treatment as prevention
THE POWER OF UNDETECTABLE What you need to know about HIV treatment as prevention CONTENTS 3 Treatment as prevention First, a few basics: What is an undetectable viral load? How do I know if I m undetectable?
More informationKey messages on syphilis for clients are available at the end of this fact sheet.
Syphilis Summary Syphilis is a sexually transmitted infection (STI) that is passed through contact with a syphilis lesion (sore or chancre). Outbreaks of syphilis have been reported in every major Canadian
More informationSyphilis FACTSHEET. Summary. What is syphilis? Who is at risk for syphilis?
FACTSHEET Syphilis Summary Syphilis is a sexually transmitted infection (STI) that is passed through contact with a syphilis lesion (sore or chancre). Outbreaks of syphilis have been reported in every
More informationMG an emerging sexually transmitted infection
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. MG an emerging sexually transmitted infection 9 October 2013 The bacterium Mycoplasma genitalium (MG) is sexually transmitted and can cause
More informationHep C treatment can cure a person from Hep C. However, a person could get infected again.
Sofosbuvir (Sovaldi) Summary Sofosbuvir is a medication used to treat Hep C. It is used in combination with other medications to cure people of the Hep C virus. Sofosbuvir is taken at a dose of 400 mg
More informationCan metformin also protect arteries?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Can metformin also protect arteries? 8 December 2011 Reports suggest that cardiovascular disease is becoming common among HIV-positive
More informationCan mirtazapine assist recovery from crystal meth addiction?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Can mirtazapine assist recovery from crystal meth addiction? 20 December 2011 Stimulants such as amphetamine and its more potent form,
More informationDoes tenofovir (TDF) cause liver injury?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Does tenofovir (TDF) cause liver injury? 10 February 2016 Tenofovir is an important antiviral drug used to treat HIV and hepatitis B virus
More informationTuberculosis FACT SHEET. Summary. What is TB?
Tuberculosis Summary Tuberculosis (TB) is caused by bacteria called Mycobacterium tuberculosis complex and usually affects the lungs. However, among people co-infected with TB and HIV, parts of the body
More informationStarting points. living with HIV
Starting points living with HIV Have you found out you have HIV and are trying to get your bearings? We can help you with the basics of living with HIV. Here s what you ll read about in this booklet: What
More informationTuberculosis FACTSHEET. Summary. What is TB?
FACTSHEET Tuberculosis Summary Tuberculosis (TB) is caused by bacteria called Mycobacterium tuberculosis complex and usually affects the lungs. However, among people co-infected with TB and HIV, parts
More informationLymphoma FACTSHEET. Summary. About the lymphatic system. Who is at risk for lymphoma? What is lymphoma?
FACTSHEET Lymphoma Summary Lymphoma is a cancer that affects a part of the immune system called the lymphatic system. Like any cancer, the earlier lymphoma is diagnosed, the easier it is to treat. In general,
More informationProgramming Connection
The H.E.R. Pregnancy Program Programming Connection Case Study Organization: Streetworks Region: Edmonton, Alberta Prepared: 2018 Quick Facts Population Street involved, Women Date Started 2011 Region
More informationHepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE
Hepatitis C Basics Michael Bailey Director of Programming, CATIE Mary Choy Regional Health Education Coordinator, CATIE CATIE Our History Learning Objectives 1) To learn about the basics of hepatitis C
More informationExciting results in monkeys lead to a clinical trial in humans
From TreatmentUpdate 219 Exciting results in monkeys lead to a clinical trial in humans A close relative of HIV called SIV (simian immunodeficiency virus) causes an AIDS-like disease in susceptible monkeys.
More informationWill de-simplification of HIV treatment become common in highincome
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Will de-simplification of HIV treatment become common in highincome countries? 13 February 2018 As more people start HIV treatment, researchers
More informationHPV, Cervical Dysplasia and Cancer
FACTSHEET HPV, Cervical Dysplasia and Cancer Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions by doctors, may persist and
More informationThe HIV testing process
FACTSHEET The HIV testing process Summary There are a few steps that a person will take in the HIV testing process. To access an HIV test, people can request a test or may be offered a test. There are
More informationThe Patient as Partner
From The Positive Side, Summer 2018 The Patient as Partner The idea that a person should be an active participant, not just a recipient, of their own healthcare has deep roots. Feminists, people living
More informationHPV, anal dysplasia and anal cancer
HPV, anal dysplasia and anal cancer Summary Anal cancer typically develops over a period of years, beginning with a precancerous condition called anal dysplasia. Anal dysplasia occurs when clusters of
More informationQuad (Stribild) Safety and effectiveness issues in depth
From TreatmentUpdate 191 Quad (Stribild) Safety and effectiveness issues in depth The FDA reviewed health-related information collected from 1,408 HIV-positive people who participated in two pivotal clinical
More informationCrystal meth interviews reveal its impact on HIV positive men
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Crystal meth interviews reveal its impact on HIV positive men 15 April 2009 Crystal meth, also known as ice or Tina, is a form of the stimulant
More information3TC (lamivudine, Epivir)
3TC (lamivudine, Epivir) Summary 3TC is a type of antiretroviral drug called a nucleoside analogue (or nuke ). 3TC can cause nausea, headache, diarrhea, vomiting and weakness; however, it causes few side
More informationHints of a cure the future of stem cell transplants and HIV
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Hints of a cure the future of stem cell transplants and HIV 21 December 2010 In 2008 a team of cancer researchers from Berlin, Germany,
More informationHepatitis C virus some background information
From TreatmentUpdate 167 Hepatitis C virus some background information Hepatitis C virus (HCV) is spread by exposure to infected blood. The following behaviours, which can expose a person to infected blood,
More informationHIV treatment and an undetectable viral load to prevent HIV transmission
HIV treatment and an undetectable viral load to prevent HIV transmission FACT SHEET Published 2018 CONTACT US Summary It is now well known that the use of HIV treatment not only improves the health of
More informationRaltegravir (Isentress)
Raltegravir (Isentress) Summary Raltegravir is a type of anti-hiv drug called an integrase inhibitor. Raltegravir is generally well tolerated. Common side effects include diarrhea, nausea and headache;
More informationI ANTI-HIV AGENTS. Contents I ANTI-HIV AGENTS II COMPLICATIONS AND SIDE EFFECTS. A. Raltegravir vs. efavirenz four. years later
TreatmentUpdate 179 Vol. 22, No. 4 May/June 2010 ISSN 11817187 Available on the World Wide Web at www.catie.ca/tu.nsf Contents I ANTI-HIV AGENTS A. Raltegravir vs. efavirenz four years later 1 B. Raltegravir
More informationToxoplasmosis FACT SHEET. What is toxoplasmosis? Symptoms CONTACT US. Published 2016
Toxoplasmosis What is toxoplasmosis? Toxoplasmosis is an infection caused by the parasite Toxoplasma gondii (T. gondii). The parasite is transmitted to people through eating undercooked meat, especially
More informationCHAPTER 1: SEXUALLY TRANSMITTED AND BLOODBORNE INFECTIONS
CHAPTER : SEXUALLY TRANSMITTED AND BLOODBORNE INFECTIONS Highlights In Peel, the incidence of Acquired Immunodeficiency Syndrome (AIDS) has remained low (. to. cases per,) since the introduction of the
More informationThe elusive AIDS vaccine
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. The elusive AIDS vaccine 4 March 2008 In the 25 years since HIV was discovered, researchers have made many strides in the fight against
More informationKey messages on chlamydia for clients are available at the end of this fact sheet.
Chlamydia Summary Chlamydia is a sexually transmitted infection caused by a bacterium. It can be transmitted through sexual contact. All people who are sexually active may be at risk for chlamydia. Chlamydia
More informationThe need for more research and boosting the brain
From TreatmentUpdate 186 The need for more research and boosting the brain When the AIDS pandemic first appeared in North America, doctors were puzzled by the sight of previously healthy young men who
More informationHarvoni (ledipasvir + sofosbuvir)
Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with all genotypes of the hepatitis C virus. Harvoni is a combination of
More informationHPV, cervical dysplasia and cervical cancer
HPV, cervical dysplasia and cervical cancer FACT SHEET Published 2016 Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions
More informationAntiviral medications can reduce the severity and frequency of genital herpes outbreaks.
Genital herpes Summary Genital herpes is a sexually transmitted infection caused by the herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2). Once a person is infected with HSV, the virus stays in the
More informationInfectious syphilis in Canada:
30 CCDR 05 February 2015 Volume 41-2 https://doi.org/10.14745/ccdr.v41i02a03 Infectious syphilis in Canada: 2003-2012 Totten S 1,*, MacLean R 1, Payne E 1 1 Centre for Communicable Diseases and Infection
More information5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1
Epidemiology 227 April 24, 2009 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 60 questions and 9 pages on the examination. Each question will count one point.
More informationHarvoni (ledipasvir + sofosbuvir)
FACTSHEET Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with genotype 1 hepatitis C virus. Harvoni is a combination of
More informationFACTSHEET. Women and the Biology of HIV Transmission
FACTSHEET Women and the Biology of HIV Transmission The majority of HIV infections are transmitted sexually and so most of the transmission occurs through the genital or reproductive systems of men and
More informationPractice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically -
ASK SCREEN Test for HIV and STI Practice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically - Routinely obtain a thorough sexual history from all
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationGonorrhea Shrinking treatment options
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Gonorrhea Shrinking treatment options 31 March 2011 Gonorrhea is a relatively common infection among men who have sex with men, but it
More informationNIH Public Access Author Manuscript Clin Infect Dis. Author manuscript; available in PMC 2009 October 1.
NIH Public Access Author Manuscript Published in final edited form as: Clin Infect Dis. 2008 October 1; 47(7): 893 899. doi:10.1086/591534. Normalization of Serum Rapid Plasma Reagin Titer Predicts Normalization
More informationSexually Transmi/ed Diseases
Sexually Transmi/ed Diseases Chapter Fourteen 2013 McGraw-Hill Higher Education. All rights reserved. Also known as sexually transmitted infections The Major STDs (STIs) HIV/AIDS Chlamydia Gonorrhea Human
More informationDaclatasvir (Daklinza)
Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in Canada for
More informationCommunicable Diseases
Communicable Diseases Communicable diseases are ones that can be transmitted or spread from one person or species to another. 1 A multitude of different communicable diseases are currently reportable in
More information3TC (lamivudine, Epivir)
FACTSHEET 3TC (lamivudine, Epivir) Summary 3TC is a type of antiretroviral drug called a nucleoside analogue (or nuke ). 3TC can cause nausea, headache, diarrhea, vomiting and weakness; however, it causes
More informationHow is it transferred?
STI s What is a STI? It is a contagious infection that is transferred from one person to another through sexual intercourse or other sexually- related behaviors. How is it transferred? The organisms live
More informationHIV prevalence and risk behaviors amongst men who have sex with. men in Hong Kong: a systematic review. (Ref. No.: R05-12)
HIV prevalence and risk behaviors amongst men who have sex with men in Hong Kong: a systematic review (Ref. No.: R05-12) (Report for CUHK I CARE Program 2012 13) Jinghua LI Ph.D. Student School of Public
More informationSome research issues with marijuana, HIV and inflammation
From TreatmentUpdate 225 Some research issues with marijuana, HIV and inflammation The body produces many compounds that cells use to send information via signals to each other. One such system of signals
More informationSyphilis among MSM: Clinical Care and Public Health Reporting
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Syphilis among MSM: Clinical Care and Public Health Reporting Kevin Ard, MD, MPH, Medical Director, National
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationIMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C
IMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C GETTING STARTED: Important things to know when you have hepatitis C If you just found out that you have hepatitis C, you may have a lot of questions.
More informationThe forgotten group: a new HIV outbreak amongst people who inject drugs. Patricia Anderson Lead CNS BBV Brownlee Centre
The forgotten group: a new HIV outbreak amongst people who inject drugs Patricia Anderson Lead CNS BBV Brownlee Centre No conflicts to declare Potted History 1981 Modern wave of drug misuse Glasgow soared
More informationTrends in Reportable Sexually Transmitted Diseases in the United States, 2007
Trends in Reportable Sexually Transmitted Diseases in the United States, 2007 National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis Sexually transmitted diseases (STDs) remain a major public
More informationOral pre-exposure prophylaxis (PrEP)
FACTSHEET Oral pre-exposure prophylaxis (PrEP) Summary Oral pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected
More information17a. Sexually Transmitted Diseases and AIDS. BIOLOGY OF HUMANS Concepts, Applications, and Issues. Judith Goodenough Betty McGuire
BIOLOGY OF HUMANS Concepts, Applications, and Issues Fifth Edition Judith Goodenough Betty McGuire 17a Sexually Transmitted Diseases and AIDS Lecture Presentation Anne Gasc Hawaii Pacific University and
More informationThe return of infectious syphilis in Ontario
The return of infectious syphilis in Ontario Michael Whelan, Epidemiologist Lead, Communicable Diseases Unit, Public Health Ontario Canadian Public Health Association Conference Vancouver, 2015 Objective:
More informationCATIE STATEMENT. on the use of condoms as a highly effective strategy to prevent the sexual transmission of HIV
CATIE STATEMENT on the use of condoms as a highly effective strategy to prevent the sexual transmission of HIV The consistent and correct use of internal (sometimes referred to as female) or external (sometimes
More informationIn Canada and around the world, the trend is clear: sexually transmitted infections (STIs) are on the rise.
Adapted From: Sexually Transmitted Infections Pamphlet. Public Health Agency of Canada, 2007 In Canada and around the world, the trend is clear: sexually transmitted infections (STIs) are on the rise.
More informationDaclatasvir (Daklinza)
FACTSHEET Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in
More informationHIV-1 Dual Infection and Neurocognitive Impairment
HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationDescovy FACTSHEET. Summary. What is Descovy? How does Descovy work?
FACTSHEET Descovy Summary Descovy is the name given to a pill containing the following two anti- HIV drugs: TAF (tenofovir alafenamide) and FTC (emtricitabine). Descovy comes in two, colour-coded strengths
More informationSaskatchewan HIV Strategy: Social Network Approach
Saskatchewan HIV Strategy: Social Network Approach Dr. Johnmark Opondo MHO Provincial Leadership Team (PLT) CATIE Forum: New Science, New Directions in HIV and HCV September 18, 2013 Toronto, Canada A
More information